Такова увеличение на белите кръвни клетки е преходно, типично се наблюдава 24- 48 часа след прилагането и е в
Therefore, physicians should exercise caution when administering Neupopeg in patients with sickle cell disease, should monitor appropriate clinical parameters and laboratory status and be attentive to the possible association of Neupopeg with splenic enlargement and vaso-occlusive crisis.